Augmentation of Nr4a3 and Suppression of Fshb Expression in the Pituitary Gland of Female Annexin A5 Null Mouse by Terashima, Ryota et al.
September 2020 | Vol. 4, Iss. 9
doi: 10.1210/jendso/bvaa096 | Journal of the Endocrine Society | 1–14
ISSN 2472-1972
Received 21 May 2020
Accepted 14 July 2020
First Published Online 16 July 2020
Corrected and Typeset 26 August 2020
Abbreviations: ANXA5, annexin A5; CGA, glycoprotein alpha subunit; rANXA5, rat annexin A5
Augmentation of Nr4a3 and Suppression of 
Fshb Expression in the Pituitary Gland of 
Female Annexin A5 Null Mouse
Ryota Terashima,1 Tomotaka Saigo,1 Titaree Laoharatchatathanin,2 Shiro Kurusu,1  
Bent Brachvogel,3 Ernst Pöschl,4 and Mitsumori Kawaminami1,5
1Laboratory of Veterinary Physiology, School of Veterinary Medicine, Kitasato University, Aomori 034-8628, 
Japan; 2Clinic for Small Domestic Animals and Radiology, Faculty of Veterinary Medicine, Mahanakorn 
University of Technology, Bangkok 10530, Thailand; 3Experimental Neonatology, Department of Pediatrics and 
Adolescent Medicine, Center for Biochemistry, Medical Faculty, University of Cologne, Cologne 50931, Germany; 
4School of Biological Sciences, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK; and 
5Laboratory of Veterinary Physiology, School of Veterinary Medicine, Okayama University of Science, Imabari, 
Ehime 794-8555, Japan
ORCiD number: 0000-0003-3165-4413 (M. Kawaminami).
  
GnRH enhances the expression of annexin A5 (ANXA5) in pituitary gonadotropes, and ANXA5 
enhances gonadotropin secretion. However, the impact of ANXA5 regulation on the expression of 
pituitary hormone genes remains unclear. Here, using quantitative PCR, we demonstrated that 
ANXA5 deficiency in female mice reduced the expression of Fshb and Gh in their pituitary glands. 
Transcriptome analysis confirmed a specific increase in Nr4a3 mRNA expression in addition to lower 
levels of Fshb expression in ANXA5-deficient female pituitary glands. This gene was then found to be 
a GnRH-inducible immediate early gene, and its increased expression caused protein to accumulate 
in the nucleus after administration of a GnRH agonist in LβT2 cells, which are an in vitro pituitary 
gonadotrope model. The increase in ANXA5 protein levels in LβT2 cells clearly suppressed Nr4a3 
expression. siRNA-mediated inhibition of Nr4a3 expression increased Fshb expression. The results 
revealed that GnRH stimulates Nr4a3 and Anxa5 sequentially. NR4A3 suppression of Fshb may be 
necessary for later massive secretion of FSH by GnRH in gonadotropes, and Nr4a3 would be nega-
tively regulated by ANXA5 to increase FSH secretion.
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GnRH of the hypothalamus promotes the secretion of gonadotropins, FSH, and LH from the 
anterior pituitary gland [1-3]. FSH and LH consist of the specific beta subunits FSHβ and 
LHβ, respectively, and the common glycoprotein alpha subunit (CGA). GnRH stimulates the 
release of gonadotropin and facilitates the expression of gonadotropin subunit genes.
A transcriptome analysis of a GnRH-stimulated mouse clonal gonadotrope cell line 
identified hundreds of regulated genes [4], and several were proposed as required for gonad-
otropin secretion. For example, in vitro study but not yet in vivo showed the transcriptional 
complex AP-1, composed of 2 GnRH-inducible factors, c-Fos and c-Jun [5], promotes the 
transcriptional activity of the Fshb promoter [6], which is needed for the GnRH-stimulated 
induction of Fshb. In addition, GnRH stimulation of high-frequency pulse induces the 
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expression of SKIL and TGIF1, which prevent the Fshb promoter activation by AP-1 [7]. 
Therefore, GnRH signaling may also induce the expression of negative regulators that may 
affect the expression of gonadotropin genes and the responsiveness of cells towards GnRH 
stimulation.
Annexin A5 (ANXA5), a calcium-dependent phosphatidylserine-binding protein [8], is 
encoded by a GnRH-inducible gene [9]. We previously demonstrated that ANXA5 is induced 
by GnRH signaling via protein kinase C activation of the MAPK pathway [10]. Moreover, 
an antisense oligonucleotide-mediated decrease in Anxa5 suppresses the secretion of LH 
by GnRH signaling in primary cultures of female rat pituitary cells [9]. A recent study also 
revealed that the administration of the GnRH agonist stimulates the expression of ANXA5 
and LHβ in the pituitary glands of female hypogonadal mice (hpg) that lack a functional 
GnRH-encoding gene [11]. These results strongly suggest that ANXA5 is involved in phys-
iological gonadotropin secretion under the influence of GnRH, but knowledge of the role of 
ANXA5 is limited.
Our previous study showed that ANXA5 is expressed in some pituitary endocrine cells 
of female rat, not only in gonadotropes [12]. Here, we examined the regulation of pitu-
itary hormone genes in ANXA5-deficient mice using transcriptome analysis and qPCR 
and identified a link between GnRH, NR4A3, ANXA5, and Fshb expression in pituitary 
gonadotrope. Sequential changes in NR4A3 and ANXA5 expression after GnRH stimulation 
is suggested to be beneficial for FSH secretion by GnRH.
Materials and Methods
Animals
All animal experiment protocols were approved by the President of Kitasato University 
through the judgment rendered by the Animal Care and Use Committee of Kitasato 
University (approval no.  15-032). The establishment of ANXA5-deficient mice (Anxa5-/-, 
Anxa5tm1Epo/Anxa5tm1Epo) has been described previously [13]. C57BL/6J wild-type and Anxa5-/- 
mice were maintained under controlled temperature and lighting: 23 ± 3°C and 14-hour 
light/10-hour dark cycle (lights on at 5:00 am). They were allowed free access to laboratory 
chow and tap water. Eight-week-old female mice were administered either 5 ng/50 µL of 
GnRH agonist (GnRHa, Des-Gly10 [Pro9]-GnRH ethylamide; Intervet K.K., Tokyo, Japan) 
or 50 µL of saline (control) through repeated IP injection (10 times in 30-minute intervals). 
Pituitary samples were collected 30 minutes after the final administration. The mice were 
sacrificed by cervical dislocation. Pituitary tissues were immediately collected and frozen 
in liquid nitrogen.
Microarray analysis
Five pituitary glands from either C57BL/6J or Anxa5-/- adult female mice were collected 
and combined. RNA was extracted using an RNeasy mini kit (Qiagen, Tokyo, Japan) ac-
cording to the manufacturer’s instructions. Microarray analysis was performed once each 
for C57BL/6J and Anxa5-/- mice (n = 1). Gene chip analysis and cDNA microarray data were 
carried out at GeneticLab Co., Ltd. (Sapporo, Japan). Briefly, the quantity and the quality 
of RNA samples digested with DNase was verified by NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific Inc, Rockford, IL) and Agilent 2100 Bioanalyzer with Agilent 
RNA 6000 Nano Kit (Agilent Technologies, Palo Alto, CA) (C57BL/6J: 3.12 µg, 2.11 OD, 
RNA integrity number score 8.3; Anxa5-/-: 3.77 µg, 2.09 OD, RNA integrity number score 
8.0). The synthesis of cDNA, cRNA, and second-cycle cDNA was performed using Ambion 
WT Expression Kit (Life Technologies, Tokyo, Japan). cDNA was fragmented and labeled 
GeneChip WT Terminal Labeling Kit (Affymetrix, Santa Clara, CA). Gene chip data were 
analyzed by means of GeneChip Scanner 3000 7G with GeneChip Mouse Gene 1.0 ST 
(Affymetrix) and GeneChip Command Console software (Affymetrix) and GeneSpring GX 
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version 11.5.1 software (Agilent Technologies). When differences in the detected gene ex-
pression levels were greater than 2-fold, the RNA expression was further measured and 
statistically evaluated by quantitative real-time PCR, as described in the following section.
Real-time PCR
Total RNA was extracted from tissues of adult female mice or cells using TRIzol rea-
gent (Life Technologies) and was reverse-transcribed to generate cDNA using a High 
Capacity cDNA synthesis kit (Life Technologies). Primer sequences for real-time PCR 
are given in Table  1. Real-time PCR was performed using Power SYBR Green PCR 
Master Mix (Life Technologies) according to the manufacturer’s protocol using the 
following amplification conditions: 95°C for 10 minutes and 50 cycles of 95°C for 15 
seconds, 60°C for 1 minute. Relative gene expression levels were calculated by the 
delta-delta CT method using ribosomal protein L19 as an internal control for nor-
malization. Melting curve analysis revealed no amplification of nonspecific products. 
Expression levels are given as the relative levels by comparing experimental levels 
with those of the relevant control sample.
Mouse gonadotrope LβT2 cell line
The LβT2 cell line was a kind gift of Prof. P. L. Mellon of the University of California, San 
Diego. The cells were maintained in DMEM with high levels of glucose (Life Technologies), 
10% fetal bovine serum (Life Technologies), and antibiotic-antimycotic supplements (Life 
Technologies); these were maintained at 37°C with 5% CO2. GnRHa (10
–8 M) was added 24 
hours after the cells were plated in multiwell plates, and they were further incubated for 
0.5, 1, 2, 4, and 8 hours. In addition, the effect of protein synthesis inhibitors was tested 
by preincubating the cells with cycloheximide (50 µM; Sigma-Aldrich, St. Louis, MO) for 2 
hours before GnRHa stimulation. The cells were also treated with recombinant rat ANXA5 
protein [10], which was added either 30 minutes before or at the same time as GnRHa 
Table 1. Primer List
Primers Forward (5′-3′) Reverse (5′-3′)
Lhb GTCTGCATCACCTTCACCAC GTAGGTGCACACTGGCTGAG
Fshb CTGCTGCCATAGCTGTGAAT GAGCTGGGTCCTTATACACCA
Cga ATCACCTGCCCAGAACACAT ACATGGACAGCATGACCAGA
Tshb CCATCAACACCACCATCTGT CCTGGTATTTCCACCGTTCT
Gh GTGGACAGATCACTGCTTGG GGAAAAGCACTAGCCTCCTG
Prl CTCAGGCCATCTTGGAGAAG TCGGAGAGAAGTCTGGCAGT
Pomc GGCCACTGAACATCTTTGTC GCGACTGTAGCAGAATCTCG
Slitrk3 CTGAGGACTCTGCCAACTGA AATGGCATTCAGGTGTTCAA
C10orf11 TACCCCACTTGCACACCTTA CAAGTTGACCAGCTCATTGG
Nr4a3 CCGAGCTTTAACAGATGCAA AGCTTCTGGACACGTCAATG
Gm7120 CGGGATTTTTAGCGTCTGTT ATGGGTATCACAGTGGAGCA
Mme TTCTGTGGCCAGACTGATTC ATTGGGTCATTTCGGTCTTC
Gm5148 CACGAACGCTGTGATCTTCT CTCATGCAAAGGGAATTGTG
Mpz TCCTTCTGGTCCAGTGAATG AAGGTTGTCCCTTGGCATAG
Mid1 CACCATATTCACCGGACAAG GTGGTTCTGCTTGATGTTGG
Fabp6 ACCATTGGCAAAGAATGTGA GACCTCCGAAGTCTGGTGAT
Akr1c18 GATAGGCCAGGCCATTCTAA AATTTTCCAAGCTGGGTCTG
Pdk4 CACCACATGCTCTTCGAACT CTACTGGGGTCAAGGAAGGA
Cetn4 ACAACTGATCGCTGAAATCG CCGTAGCATCGTCATCAAAT
Grp TCAGTCTCCAGCCTACTTGG TCCTCCCTTTTCCTTGAGAA
Anxa5 GGTACCGATGAGGACAGCAT TCCCTGCCAAACAGAGTCTT
Rpl19 AGCCTGTGACTGTCCATTCC GCATTGGCAGTACCCTTCCT
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administration. For immunoblotting, the cells were cultured in 35-mm dishes. The cells 
were harvested in Laemmli sample buffer after incubation with GnRHa (10–8 M) or fol-
lowing transfection of the expression vector.
Western blotting
LβT2 cell lysates were loaded on a 12% SDS-PAGE gel and then were transferred to 
polyvinylidene fluoride membranes (Amersham Hybond P 0.45, GE Healthcare UK Ltd, 
Buckinghamshire, UK). After blocking with 5% nonfat milk in Tris-buffered saline and 
Tween 20, the membranes were probed with primary antibodies against NR4A3 (1:1000 di-
lution; anti-human NGFI-B gamma mouse monoclonal antibody; Perseus Proteomics Inc., 
Tokyo, Japan) [14], ANXA5 (1:10 000 dilution; polyclonal rabbit sera against rat ANXA5) 
[15], and β-actin (1:2000 dilution; mouse monoclonal sc-47778, Santa Cruz Biotechnology, 
Santa Cruz, CA) [16] at 4°C overnight. Then, the membranes were incubated with an ECL 
peroxidase-labeled anti-mouse antibody or anti-rabbit antibody (GE Healthcare UK Ltd) 
[17, 18], which function as a secondary antibody. Immunoreactivity was detected by chem-
iluminescence with ECL Western blotting detection reagents (GE Healthcare UK Ltd), 
and blots were scanned using an ImageQuant LAS 4000 system (GE Healthcare UK Ltd).
Immunocytochemistry
LβT2 cells were seeded on poly-L-lysine-coated coverslips and were grown for 2 days. 
After incubation with GnRHa (10–8 M), the cells were fixed with 4% paraformaldehyde-
PBS at room temperature for 10 minutes and then were blocked by incubating with 
10% normal goat serum for 30 minutes. Immunocytochemistry was performed using 
an indirect immunofluorescence technique with an anti-NR4A3 primary antibody 
(1:2000) and an Alexa Fluor 488 goat anti-mouse IgG secondary antibody (1:200; Life 
Technologies) [19]. To visualize the actin cytoskeleton, F-actin was stained with Alexa 
Fluor 568 phalloidin (Life Technologies) for 30 minutes. The specimens were mounted 
with VECTASHIELD mounting medium with DAPI (Vector Laboratories, Burlingame, 
CA), and they were visualized using a confocal laser microscope (LSM710, Carl Zeiss 
Japan, Tokyo, Japan).
Transfection of the vector and siRNA
Rat Anxa5 cDNA was previously cloned into BamHI site of plasmid pUC119 [20], 
subcloned into BamHI site of plasmid pcDNA3.1(-) (Invitrogen, Carlsbad, CA) and 
sequenced (LC533519). The transfection of the expression vectors for ANXA5 (pcANXA5) 
was performed by means of electroporation using an NEPA21 electroporator and electro-
poration cuvettes (Nepa Gene Co. Ltd., Chiba, Japan). A suspension of LβT2 cells (106 
cells/100 µL) was prepared by detaching the cells with trypsin, and the cells were then 
mixed with 10 µg plasmid vector and electroporated by applying 2 pulses of 175 V for 
5 ms at 50-ms intervals.
Nr4a3 Silencer Select siRNA (ID: s70687) and Silencer Select Negative Control #1 siRNA 
were obtained from Ambion (Austin, TX). LβT2 cells were transfected with each type of 
siRNA (66 pmol/mL final concentration) using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions.
After transfection with the expression vectors or siRNA, the cells were incubated for 48 
hours and then they were treated with GnRHa (10–8 M).
Statistics
The results are presented as the mean ± SEM. Significant differences were analyzed with 
Student t tests or 1- or 2-way ANOVA followed by a Tukey-Kramer test. A P value less than 
0.05 was considered statistically significant.
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Results
Expression changes in the anterior pituitary glands of Anxa5-/- mice
To determine the effect of ANXA5 deficiency on anterior pituitary gland hormone produc-
tion, we analyzed the relative expression levels in RNA extracts from the pituitary glands 
of C57BL/6J mouse controls and Anxa5-/- mutants using real-time PCR. Among the 7 pitu-
itary hormone genes analyzed, we observed that the FSH beta subunit (Fshb) and Gh ex-
pression levels were significantly reduced in the Anxa5-/- pituitary glands (Fig. 1). We also 
studied global expression changes and performed a transcriptome analysis of the anterior 
pituitary glands of C57BL/6J and Anxa5-/- mice. The results from the microarray analysis 
showed a 1.4-fold decrease in Fshb mRNA in the Anxa5-/- pituitary glands compared with 
the level of the control, whereas the expression of Gh and other pituitary hormone genes 
remained unchanged compared with that of the control (Table 2). Fourteen of 23 304 genes 
were differentially expressed, as defined by having a 2-fold or greater difference. To confirm 
the results, quantitative PCR analysis was performed. Here, we confirmed that Slitrk3, 
C10orf11, Nr4a3, and Mme were upregulated 2.9-, 7.0-, 6.8-, and 4.3-fold, respectively, and 
Mid1 was downregulated 6.7-fold in the pituitary glands of Anxa5-/- mice (Fig. 2).
ANXA5-controlled genes responding to GnRH stimulus in the pituitary glands
To identify the GnRH-responsive genes within the cluster of differentially expressed genes, 
C57BL/6J mice were received multiple administrations of GnRHa or saline. Then, RNA 
from their pituitary glands was isolated, and relative gene expression was determined 
using quantitative PCR. Here, we observed that the administration of GnRHa significantly 
increased Nr4a3 expression 2-fold and decreased Akr1c18 expression 3-fold in the pituitary 
glands compared with the levels determined for the saline control (Fig. 3). AKR1C18 is a 
20α-hydroxysteroid dehydrogenase that converts progesterone to the nonactive metabolite 
Figure 1. Pituitary hormone gene expression in Anxa5-/- mice. The levels of Lhb, Fshb, 
Cga, Tshb, Gh, Prl, and Pomc mRNA expression in wild-type (C57BL/6) and Anxa5-/- mice 
were analyzed by quantitative real-time PCR. Data are depicted as the mean ± SEM (n = 5). 
Statistical analysis was performed with Student t tests (*P < 0.05). ANXA5, annexin A5; Cga, 
common alpha glycoprotein subunit; Fshb, follicle stimulating hormone beta subunit; Lhb, 
luteinizing hormone beta subunit; Pomc, pro-opiomelanocortin; Prl, prolactin; Tshb, thyroid 
stimulating hormone beta subunit.
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20α-hydroxyprogesterone in ovaries [21]. Akr1c18 was shown to be induced by PPARalpha 
in the pituitary gland [22]. In addition, we confirmed a previously described increase in the 
expression of Anxa5.
Figure 2. Expression levels of the 13 genes affected by ANXA5 deficiency in the pituitary 
glands listed in Table 2. Relative mRNA levels in the pituitary glands of C57BL/6 and Anxa5-/-  
mice were measured by real-time quantitative PCR, and the relative expression levels in the 
control animals were set at 1.0. Data are depicted as the mean ± SEM (n = 5). Statistical ana-
lysis was performed with Student t tests (**P < 0.01). ANXA5, annexin A5.
Table 2. Gene Expression in the Pituitary Gland of Anxa5-/- Mice
Gene ID Gene Description Gene symbol Fold change
Genes upregulated in the anterior pituitary gland of Anxa5-/-
NM_198864 SLIT and NTRK-like family, member 3 Slitrk3 2.84
NM_028275 RIKEN cDNA 1700112E06 gene  
(leucine-rich repeat-containing protein C10orf11 homolog)
C10orf11 2.64
NM_015743 Nuclear receptor subfamily 4, group A, member 3 Nr4a3 2.28
NM_001039244 Predicted gene 7120 Gm7120 2.09
NM_008604 Membrane metalloendopeptidase (CD10) Mme 2.02
Genes downregulated in the anterior pituitary gland of Anxa5-/-
NM_198657 Predicted gene 5148 Gm5148 -4.71
NM_008623 Myelin protein zero Mpz -4.20
NM_010797 Midline 1 (Tripartite motif protein 18) Mid1 -3.16
NM_008375 Fatty acid binding protein 6 (gastrotropin) Fabp6 -2.73
NM_134066 Aldo-ketoreductase family 1, member C18 Akr1c18 -2.46
NM_013743 Pyruvate dehydrogenase kinase, isoenzyme 4 Pdk4 -2.46
NM_009673 Annexin A5 Anxa5 -2.19
NM_145825 Centrin 4 Cetn4 -2.02
NM_175012 Gastrin releasing peptide Grp -2.00
Pituitary hormone genes
NM_008497 LH beta Lhb 1.05
NM_008045 FSH beta Fshb -1.41
NM_009889 Glycoprotein hormones, alpha subunit Cga 1.02
NM_00943 TSH beta Tshb 1.10
NM_008117 GH Gh -1.01
NM_011164 Prolactin Prl -1.00
NM_008895 Pro-opiomelanocortin-alpha Pomc 1.10
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Induction and intranuclear accumulation of NR4A3 by GnRH
Interestingly, Nr4a3 expression was increased in Anxa5-/- pituitary gland tissue, and GnRH 
could induce Nr4a3 and Anxa5 expression. Therefore, we compared the levels of Anxa5 
and Nr4a3 expression in the mouse gonadotrope cell line LβT2. GnRHa stimulation caused 
a single peak of transiently increased Nr4a3 mRNA expression 1 hour after stimulation 
(Fig. 4A). In contrast, Anxa5 mRNA expression showed a constant increase 8 hours after the 
LβT2 cells were treated (Fig. 4B). To examine whether the synthesis of Nr4a3 mRNA was 
dependent on protein synthesis, LβT2 cells were incubated with the protein synthesis in-
hibitor before GnRHa treatment. The kinetics of Nr4a3 mRNA expression were not affected 
by the addition of the inhibitor. Hence, Nr4a3 is a direct immediate early gene of GnRH, 
and stimulation of Nr4a3 mRNA expression is independent of protein synthesis processes 
(Fig. 4C). The results from the immunoblot analysis showed that the increase in mRNA 
expression was accompanied by a peak of increased NR4A3 protein (~75 kD band) expres-
sion 2 hours after GnRHa stimulation (Fig. 4D). Immunocytochemistry clearly showed that 
NR4A3 protein levels were increased, and NR4A3 was detected within the nuclei of the 
LβT2 cells after GnRHa treatment (Fig. 4E).
Inhibitory effect of de novo synthesized and exogenous ANXA5 on Nr4a3 expression
Because Nr4a3 expression is enhanced in the pituitary glands of ANXA5-deficient mice, we 
hypothesized that Nr4a3 expression is inhibited in the presence of ANXA5. We therefore 
studied the effect of increasing ANXA5 levels on Nr4a3 mRNA expression in LβT2 cells using 
transient transfection protocols (Fig. 5A). ANXA5 expression was successfully increased two 
days after transfection, and the Nr4a3 mRNA levels were significantly reduced compared 
with the levels in the control cells after GnRH stimulation (Fig. 5B). We previously showed 
a stimulatory effect of externally added recombinant rat ANXA5 (rANXA5) on gonadotropin 
release from primary pituitary cells [9], which indicated that exogenous ANXA5 can act 
on gonadotropes to cause release the hormone. Therefore, the LβT2 cells were simultane-
ously incubated with GnRHa and rANXA5 to study the combined effect on Nr4a3 expres-
sion. The administration of rANXA5 in addition to GnRHa significantly inhibited Nr4a3 
mRNA expression after 1 hour in a dose-dependent manner (Fig. 5C). The preincubation 
Figure 3. Effects of GnRHa stimulation on genes differentially expressed in ANXA5-
deficient pituitary glands. C57BL/6 control mice were repeatedly administered a GnRH 
agonist (GnRHa, 5 ng/50 µL, 10 times) to obtain a large response, or they were administered 
saline alone; then, relative mRNA levels in the pituitary glands were measured by real-time 
quantitative PCR. Data are depicted as the mean ± SEM (n = 5). Statistical analysis was per-
formed with Student t tests (*P < 0.05). ANXA5, annexin A5.
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with rANXA5 for 30 minutes (Fig. 5D) or the preincubation and simultaneous incubation 
with GnRHa (Fig. 5E) showed a similar inhibitory effect on Nr4a3 mRNA expression.
Effect of Nr4a3 on gonadotropin gene expression
Next, we used siRNA to knock down Nr4a3 in LβT2 cells so that we could determine whether 
NR4A3 could regulate gonadotropin gene expression. The Nr4a3 mRNA levels were significantly 
Figure 4. Induction of Nr4a3 expression and accumulation of NR4A3 protein in the nuclei 
after GnRH stimulation in gonadotrope cell line LβT2. (A) Nr4a3 and (B) Anxa5 mRNA 
expression was observed after LβT2 cells were incubated with GnRHa (10–8 M) for 0 to 8 
hours (mean ± SEM; n = 4). Statistical analysis was performed with 1-way ANOVA and a 
Tukey-Kramer test (**P < 0.01 vs 0 hours). (C) LβT2 cells were preincubated with or without 
cycloheximide (CHX, 50 µM) for 2 hours. Nr4a3 mRNA expression was measured after 
GnRHa (10–8 M) treatment for 1 hour (mean ± SEM; n = 4). Statistical analysis was per-
formed with 2-way ANOVA and a Tukey-Kramer test (**P < 0.01). NR4A3 protein expression 
was observed by (D) Western blotting and (E) immunocytochemistry of LβT2 cells in the 
presence of GnRHa (10–8 M) for 0 to 8 hours and 0 to 4 hours, respectively. (E) Distribution 
of the NR4A3 protein (green), actin cytoskeleton (red) and nuclei (blue) in cell aggregates 
was observed by confocal laser scanning microscopy. Scale bars indicate 10 µm (E). ANXA5, 
annexin A5.
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article/4/9/bvaa096/5872088 by U
niversity of East Anglia user on 14 Septem
ber 2020
doi: 10.1210/jendso/bvaa096 | Journal of the Endocrine Society | 9
reduced between 1 and 2 hours after GnRHa administration (expression ratio of NR4A3 siRNA 
transfected cells to control siRNA transfected cells: 0 hours, 55%; 1 hours, 66%; 2 hours, 47%; 
4 hours, 56%; 8 hours, 62%) (Fig. 6A); further, Fshb mRNA expression, which is known to be 
increased after stimulation, was increased in the siRNA for NR4A3 transfected cells between 
1 and 8 hours after GnRHa administration compared with the expression levels observed in 
the control cells (Fig. 6B). Lhb mRNA expression levels showed a 40% decrease within the first 
2 hours of GnRHa administration, and thereafter, normal levels were reestablished (Fig. 6C); 
however, the expression of the common alpha subunit (Cga) mRNA was not significantly al-
tered in the NR4A3 siRNA transfected LβT2 cells (Fig. 6D). This finding suggests that the 
induction of NR4A3 by GnRH can suppress Fshb gene expression.
Discussion
Here, we demonstrated a unique system for regulating Fshb expression among gonado-
tropin subunits through GnRH and ANXA5 in pituitary gonadotropes. Although GnRH 
Figure 5. Suppression of Nr4a3 expression by ANXA5. (A) LβT2 cells were transfected with 
an ANXA5 expression vector (pcANXA5) or an empty vector (pcDNA), and the expression of 
the ANXA5 protein was detected by Western blotting for mouse and rat ANXA5 protein. (B) 
Nr4a3 mRNA expression in the cells transfected with pcANXA5 or pcDNA was measured 
after induction with GnRHa (10–8 M) for 1 hour (mean ± SEM; n = 4; *P < 0.05, **P < 0.01). 
(C-E) LβT2 cells were incubated for 1 hour in the absence or presence of GnRHa (10–8 M), 
and the Nr4a3 mRNA levels were measured (mean ± SEM; n = 4; **P < 0.01). Recombinant 
ANXA5 (rANXA5, 0-10 µg/mL) was used as a treatment in the 3 conditions: simultaneous 
administration with GnRHa (C, simultaneous), preadministration 30 minutes before incu-
bation with GnRHa alone (D, pre), or preadministration and simultaneous administration 
(E, pre+simultaneous). Statistical analysis was performed with 2-way ANOVA and a Tukey-
Kramer test. ANXA5, annexin A5.
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stimulates both LH and FSH secretion, the secretion patterns of these hormones are not 
always identical. Therefore, specific regulation for each subunit has been presumed.
Mittag et al. first reported that Fshb mRNA expression levels were specifically lowered 
among anterior pituitary hormone genes in immature 3-week-old male Anxa5-/- mice [23]. 
Because ANXA5 was suggested to enhance the expression of Fshb mRNA, we have now 
identified the genes specifically regulated in ANXA5-deficient pituitary glands of adult fe-
male mice. The present study shows a regulatory network involving ANXA5 and the tran-
scription factor NR4A3, and both were enhanced by GnRH in pituitary gonadotrope cells. 
NR4A3 is proposed to suppress the expression of Fshb mRNA.
The expression of Nr4a3 is enhanced in the ANXA5-deficient pituitary glands, and, in con-
trast, its expression is suppressed by the overexpressed ANXA5 protein such that ANXA5 
represents a negative regulator of Nr4a3 expression. The effect of ANXA5 on NR4A3 was 
highly effective as preadministration of ANXA5 elicited the same effect as when ANXA5 
was given with GnRHa. In turn, NR4A3 was suggested to suppress Fshb mRNA because 
Figure 6. Effect of RNA interference targeting Nr4a3 on gonadotropin genes. LβT2 cells 
were transfected with an Nr4a3-specific siRNA (Nr4a3 siRNA; filled triangle) or a nega-
tive control siRNA (control; open circle), and then the cells were incubated for 48 hours. (A) 
Nr4a3, (B) Fshb, (C) Lhb, and (D) Cga mRNA expression in cells treated with GnRHa (10–8 
M) was measured by quantitative PCR at 0 to 8 hours (mean ± SEM; n = 4). Relative levels 
of mRNA are indicated compared with levels of the control group at the start (0 hours) of 
treatment. Statistical analysis was performed with 2-way ANOVA and a Tukey-Kramer test 
(**P < 0.01). *P < 0.05 and **P < 0.01 indicate comparison to the levels at 0 hours under the 
same conditions as those of the siRNA transfected cells; #P < 0.05 and ##P < 0.01 indicate 
comparison to the control group at each time point.
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overexpression of Nr4a3 in ANXA5-deficient mice accompanied decreased Fshb expression 
and the suppression of Nr4a3 by siRNA augmented Fshb mRNA expression.
Here, we demonstrated the influence of ANXA5 and NR4A3 on Fshb mRNA expression. 
Nr4a3 was shown to be an immediate early gene induced by the GnRH receptor. NR4A3 
(also known as neuron-derived orphan receptor 1) is known as a nuclear orphan receptor 
in the NR4A protein family, which includes NR4A1 and NR4A2. It has been reported that 
the NR4A protein is induced by various stimuli, including the activation of GPCRs [24-31]. 
In the present study, the NR4A3 protein immediately accumulated in the nucleus upon 
GnRHa administration. The NR4A protein was also reported to translocate into nuclei in a 
ligand-independent manner [32]. Our data further support the idea that NR4A3 has a pri-
mary role in regulating gene expression upon GnRH stimulation. Because ANXA5 expres-
sion is also stimulated by GnRH after NR4A3, we assume that the sequential expression 
of NR4A3 and ANXA5 may define a regulatory network linked with GnRH effects on FSH 
secretion.
In Nr4a3 knockdown experiments, the increase in Fshb mRNA following GnRHa ad-
ministration continued for at least 8 hours after administration. This result suggests that 
the transient increase in NR4A3 after GnRHa stimulation elicits long-lasting effects, such 
as the following: (1) direct inhibition of Fshb transcription activity, (2) repression of the ef-
fector of Fshb expression, and (3) suppression of Fshb mRNA stability. Verification of mul-
tiple aspects of this mechanism, such as measuring transcription activity by reporter gene 
assay and analyzing direct DNA binding by chromatin immunoprecipitation assay, will be 
helpful for elucidating the effect of NR4A3 on Fshb mRNA expression.
NR4A3 is known as a nuclear receptor that is predicted to interact with a specific sequence. 
To date, we do not know how NR4A3 affects Fshb mRNA expression, and we need to examine 
the relationship between NR4A3 and the reported gene products that affected Fshb mRNA. 
Because NR4A3 was shown to interact with the SIX3 homeodomain transcription factor 
and SIX3 is expressed in gonadotropes [33, 34], we assume the involvement of the interac-
tion between NR4A3 and SIX3 in the functional network of GnRH-ANXA5-NR4A3-Fshb.
Although various molecular functions have been proposed for ANXA5, including the inhi-
bition of protein kinase C [35], the formation of calcium channels in phospholipid membranes 
[36], the binding of calcium ions, and the interaction with actin and collagen [37, 38], the 
physiological significance of these functions is still unknown. Therefore, the functional re-
lationship between ANXA5 and NR4A3 expression is a part of the next subject of inves-
tigation into the molecular mechanism for ANXA5 function. Although the present study 
showed that ANXA5 enhances FSH synthesis, it is not known how it works physiologically. 
We have already revealed that ANXA5 augments gonadotropin secretion [9], but ANXA5-
deficient mice exhibit regular estrous cycles and ovulation numbers [39]. Brachvogel et al. 
also did not observe any apparent phenotype in reproductive function in ANXA5-/- [13]. This 
is probably because of the presence of a redundant mechanism of the other annexin family 
members, ANXA1 through 13, 12 does not exist. Recently, we demonstrated that the expres-
sion of ANXA1 is also facilitated by GnRH [40]. Further analysis of ANXA5 function as it 
relates to gonadotropin secretion is needed.
It is well known that FSH and LH have different secretion patterns. This difference is 
sometimes explained by the difference in the pulsatile pattern of GnRH release. The in-
crease in GnRH pulse frequency leads to downregulation of FSH synthesis and release, 
which is recognized as one of the switching processes between follicular development and 
maturation [41-43]. This inhibitory mechanism is suggested to be involved in the suppres-
sion of Fshb under high-frequency GnRH stimulation, in which negative effectors on Fshb 
gene transcription, such as ICER, SKIL, and TGIF1, are induced [7, 44, 45]. Because Nr4a3 
is transiently induced by GnRH as an immediate early gene and is suggested to specifically 
suppress the Fshb gene expression level, NR4A3 would also be involved in the frequency-
dependent mechanism by which GnRH regulates FSH secretion.
The present results clearly demonstrate a specific functional relationship among GnRH, 
ANXA5, and NR4A3. GnRH stimulation of NR4A3 expression that is suggested to suppress 
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FSH expression is followed by augmentation of ANXA5 that downregulates NR4A3 expres-
sion. This proposed relationship would consist of a regulatory network that controls Fshb 
expression through association with the mechanisms that establish the harmonized secre-
tion of LH and FSH.
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